Hims & Hers Health (HIMS) Stock Forecast & Price Target

Q: What is HIMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 25.32.

Q: What is HIMS’s upside potential, based on the analysts’ average price target?

Hims & Hers Health has 2.22% upside potential, based on the analysts’ average price target.

Q: Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

Q: How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Q: Is HIMS a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Moderate Buy which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.

Q: What is Hims & Hers Health’s price target?

The average price target for Hims & Hers Health is 25.32. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $35.00 ,the lowest forecast is $17.00. The average price target represents 2.22% Increase from the current price of $24.77.

Q: What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

Q: How can I buy shares of HIMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Compare

9,212 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIMS Analyst Ratings

Moderate Buy

4 Buy

10 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Hims

& Hers Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$25.32

▲(2.22% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $25.32 with a high forecast of $35.00 and a low forecast of $17.00. The average price target represents a 2.22% change from the last price of $24.77.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","27":"$27","39":"$39","51":"$51","63":"$63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25.32,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$25.32</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,27,39,51,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.48,17.904615384615386,19.32923076923077,20.753846153846155,22.17846153846154,23.603076923076923,25.02769230769231,26.45230769230769,27.876923076923077,29.301538461538463,30.726153846153846,32.15076923076923,33.57538461538462,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.48,17.16,17.84,18.52,19.2,19.88,20.560000000000002,21.240000000000002,21.92,22.6,23.28,23.96,24.64,{"y":25.32,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,16.48,16.52,16.56,16.6,16.64,16.68,16.72,16.76,16.8,16.84,16.88,16.92,16.96,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":45.09,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.16,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.77,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.31,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.46,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.47,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 82, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.44,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 104, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":16.48,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 118, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$35.00

Average Price Target$25.32

Lowest Price Target$17.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Glen Santangelo

Barclays

$25→$29

Buy

17.08%

Upside

Assigned

03/11/26

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)

Allen Lutz

Bank of America Securities

$12.5→$23

Hold

-7.15%

Downside

Upgraded

03/10/26

Hims & Hers upgraded to Neutral from Underperform at BofAHims & Hers upgraded to Neutral from Underperform at BofA

George Hill

Deutsche Bank

$25→$28

Hold

13.04%

Upside

Reiterated

03/10/26

Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank

Daniel Grosslight

Citi

$13.25→$24

Hold

-3.11%

Downside

Upgraded

03/10/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

03/10/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), ARS Pharmaceuticals (NASDAQ: SPRY) and Revolution Medicines (NASDAQ: RVMD)

Maria Ripps

Canaccord Genuity

$30

Buy

21.11%

Upside

Reiterated

03/09/26

Re-Rating Hims & Hers: Novo Nordisk Partnership De-Risks GLP-1 Exposure and Supports Further Multiple Expansion

Craig Hettenbach

Morgan Stanley

$21

Hold

-15.22%

Downside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Ryan MacDonald

Needham

$30

Buy

21.11%

Upside

Upgraded

03/09/26

Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)

Unknown Analyst

Nephron

Not Ranked

Nephron

$35

Buy

41.30%

Upside

Upgraded

03/09/26

Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research

David Larsen

BTIG

―

Hold

―

Reiterated

03/05/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Mark Mahaney

Evercore ISI

$33→$24

Hold

-3.11%

Downside

Reiterated

02/24/26

Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI

Justin Patterson

KeyBanc

―

Hold

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)

Michael Cherny

Leerink Partners

$20→$17.5

Hold

-29.35%

Downside

Reiterated

02/24/26

Hims & Hers price target lowered to $17.50 from $20 at LeerinkHims & Hers price target lowered to $17.50 from $20 at Leerink

Jonna Kim

TD Cowen

$20→$17

Hold

-31.37%

Downside

Reiterated

02/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Summit Therapeutics (NASDAQ: SMMT)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$30

Sell

21.11%

Upside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Glen Santangelo

Barclays

$25→$29

Buy

17.08%

Upside

Assigned

03/11/26

Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (NYSE: HIMS) and Medtronic (NYSE: MDT)

Allen Lutz

Bank of America Securities

$12.5→$23

Hold

-7.15%

Downside

Upgraded

03/10/26

Hims & Hers upgraded to Neutral from Underperform at BofAHims & Hers upgraded to Neutral from Underperform at BofA

George Hill

Deutsche Bank

$25→$28

Hold

13.04%

Upside

Reiterated

03/10/26

Hims & Hers price target raised to $28 from $25 at Deutsche BankHims & Hers price target raised to $28 from $25 at Deutsche Bank

Daniel Grosslight

Citi

$13.25→$24

Hold

-3.11%

Downside

Upgraded

03/10/26

Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH), Myomo (NYSE MKT: MYO) and Hims & Hers Health (NYSE: HIMS)

Jailendra Singh

Truist Financial

―

Hold

―

Reiterated

03/10/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS), ARS Pharmaceuticals (NASDAQ: SPRY) and Revolution Medicines (NASDAQ: RVMD)

Maria Ripps

Canaccord Genuity

$30

Buy

21.11%

Upside

Reiterated

03/09/26

Re-Rating Hims & Hers: Novo Nordisk Partnership De-Risks GLP-1 Exposure and Supports Further Multiple Expansion

Craig Hettenbach

Morgan Stanley

$21

Hold

-15.22%

Downside

Reiterated

03/09/26

Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL), Hims & Hers Health (NYSE: HIMS) and Regeneron (NASDAQ: REGN)

Ryan MacDonald

Needham

$30

Buy

21.11%

Upside

Upgraded

03/09/26

Analysts Offer Insights on Healthcare Companies: NovaBridge Biosciences (NASDAQ: NBP) and Hims & Hers Health (NYSE: HIMS)

Unknown Analyst

Nephron

Not Ranked

Nephron

$35

Buy

41.30%

Upside

Upgraded

03/09/26

Hims & Hers upgraded to Buy from Hold at Nephron ResearchHims & Hers upgraded to Buy from Hold at Nephron Research

David Larsen

BTIG

―

Hold

―

Reiterated

03/05/26

Analysts Conflicted on These Healthcare Names: Hims & Hers Health (NYSE: HIMS) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Mark Mahaney

Evercore ISI

$33→$24

Hold

-3.11%

Downside

Reiterated

02/24/26

Hims & Hers price target lowered to $24 from $33 at Evercore ISIHims & Hers price target lowered to $24 from $33 at Evercore ISI

Justin Patterson

KeyBanc

―

Hold

―

Reiterated

02/24/26

Analysts Offer Insights on Healthcare Companies: Brookdale Senior Living (NYSE: BKD), Kyntra Bio (NASDAQ: KYNB) and Hims & Hers Health (NYSE: HIMS)

Michael Cherny

Leerink Partners

$20→$17.5

Hold

-29.35%

Downside

Reiterated

02/24/26

Hims & Hers price target lowered to $17.50 from $20 at LeerinkHims & Hers price target lowered to $17.50 from $20 at Leerink

Jonna Kim

TD Cowen

$20→$17

Hold

-31.37%

Downside

Reiterated

02/23/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (NYSE: HIMS) and Summit Therapeutics (NASDAQ: SMMT)

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$30

Sell

21.11%

Upside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months

xxx

Success Rate

9/12 ratings generated profit

Average Return

+26.96%

reiterated a xxx

rating 7 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +26.96% per trade.

1 Year

Glen SantangeloBarclays

Success Rate

7/9 ratings generated profit

Average Return

+35.73%

assigned a buy rating 5 days ago

Copying Glen Santangelo's trades and holding each position for 1 Year would result in 77.78% of your transactions generating a profit, with an average return of +35.73% per trade.

2 Years

xxx

Success Rate

7/9 ratings generated profit

Average Return

+37.00%

assigned a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 77.78% of your transactions generating a profit, with an average return of +37.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

104

118

Sell

Strong Sell

total

126

143

In the current month, HIMS has received 16 Buy Ratings, 118 Hold Ratings, and 9 Sell Ratings. HIMS average Analyst price target in the past 3 months is 25.32.

Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is <$0.01 with a range of -$0.21 to $0.15. The previous quarter’s EPS was $0.08. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $616.50M with a range of $608.37M to $632.50M. The previous quarter’s sales results were $617.82M. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is HIMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 25.32.

What is HIMS’s upside potential, based on the analysts’ average price target?

Hims & Hers Health has 2.22% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HIMS a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Moderate Buy which is based on 4 buy ratings, 10 hold ratings and 0 sell ratings.

What is Hims & Hers Health’s price target?

The average price target for Hims & Hers Health is 25.32. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $35.00 ,the lowest forecast is $17.00. The average price target represents 2.22% Increase from the current price of $24.77.

What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of HIMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hims & Hers Health (HIMS) Stock Forecast & Price Target

HIMS Analyst Ratings

HIMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hims & Hers Health

HIMS Analyst Recommendation Trends

HIMS Financial Forecast

HIMS Earnings Forecast

HIMS Sales Forecast

HIMS Stock Forecast FAQ

Detailed List of Analyst Forecasts